GURU.Markets stock price, segment price, and overall market index valuation
The company's share price Heart Test Laboratories
Shares of Heart Test Laboratories, a medical device company developing an AI-powered ECG test, are a bet on its technology. The price chart reflects the company's dependence on successful clinical trials and regulatory approval for its diagnostic device.
Share prices of companies in the market segment - Medanalysis
Heart Test Laboratories is developing MyoVista, a medical device that uses ECG for the early detection of heart disease. We've categorized it as a "Medanalysis" device. The chart below shows how the market is evaluating innovative technologies in cardiac diagnostics.
Broad Market Index - GURU.Markets
Heart Test Laboratories is a medical device company developing an AI-powered ECG test for the early detection of heart disease. Its innovative approach makes it a key component of the GURU.Markets index. The chart below represents the entire market. Find out how Heart Test compares to it.
Change in the price of a company, segment, and market as a whole per day
HSCS - Daily change in the company's share price Heart Test Laboratories
The daily price change of Heart Test Laboratories, Inc. reflects volatility in the medical device sector. The indicator demonstrates sensitivity to news about the development and approval of its AI-powered ECG device for diagnosing heart disease.
Daily change in the price of a set of shares in a market segment - Medanalysis
Heart Test Laboratories develops cardiac diagnostic devices, and its volatility reflects advances in medical technology. The chart below shows average daily fluctuations in the medical testing sector. This provides a benchmark for comparing how riskier or more stable HSCS stock is compared to its peers.
Daily change in the price of a broad market stock, index - GURU.Markets
Heart Test Laboratories is developing technology for the early diagnosis of heart disease using ECG. Shares of this innovative medical technology company are responding to clinical advances and regulatory decisions, contributing to the overall volatility of the healthcare sector.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization Heart Test Laboratories
Heart Test Laboratories' year-over-year performance is a story about the commercialization of its MyoVista® device for the early detection of heart disease. Its 12-month market cap hinges on its success in securing regulatory approvals and convincing physicians of the value of its AI-powered ECG test, which is key to its commercial success.
Annual dynamics of market capitalization of the market segment - Medanalysis
Heart Test, a company developing an AI-powered ECG device, is betting on medical innovation. Its performance relative to the sector will reveal how much investors believe in its ability to commercialize its unique technology and secure regulatory approval.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
Heart Test Laboratories, a company specializing in cardiac diagnostics, is at the intersection of healthcare and technology. Its year-over-year market capitalization reflects not only general investor sentiment but also specific expectations related to the approval of new medical devices and their commercial potential in combating a global problem.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization Heart Test Laboratories
Heart Test Labs is developing a medical device for diagnosing heart disease. Currently in the commercialization stage, its monthly valuation depends on progress toward FDA approval and initial sales. Clinical data updates are key.
Monthly dynamics of market capitalization of the market segment - Medanalysis
Heart Test Laboratories, Inc. is a medical technology company that developed the MyoVista device for the early diagnosis of heart disease using ECG. The dynamics of its sector, shown in the graph, reflect innovation in medicine. Against this backdrop, one can appreciate how its non-invasive technology can help detect ischemia at its early stages.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
Heart Test Laboratories develops devices for diagnosing heart disease. The company's shares are driven by news of clinical trials and regulatory approvals. The chart will show little correlation with the market, as investors evaluate the potential of the medical device rather than overall economic trends.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization Heart Test Laboratories
Heart Test Laboratories is developing an AI-powered electrocardiograph for the early detection of heart disease. Its weekly stock price is a bet on the commercial success of this innovative diagnostic technology.
Weekly dynamics of market capitalization of the market segment - Medanalysis
Heart Test Laboratories develops devices for the early diagnosis of heart disease. The chart compares the weekly performance of this medtech company's stock with its sector. Are the sharp price movements a reaction to news about clinical trials or is this a general trend in cardiology?
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
As a medical technology company, Heart Test Laboratories should be less dependent on economic cycles. The chart will show how insulated the company's shares are from general market fluctuations, moving with product news and regulatory decisions while ignoring macroeconomic noise.
Market capitalization of the company, segment and market as a whole
HSCS - Market capitalization of the company Heart Test Laboratories
The Heart Test Laboratories chart shows the market's attempt to value a new diagnostic technology. The market cap of this company, which has developed an AI-powered ECG device for the early detection of heart disease, reflects investors' belief that its technology could become a new standard in cardiology.
HSCS - Share of the company's market capitalization Heart Test Laboratories within the market segment - Medanalysis
Heart Test Laboratories has developed the MyoVista medical device, which uses ECG for the early detection of heart disease. Its market capitalization in the medical analytics segment reflects the potential of this technology. The company's clout is a bet that its inexpensive and rapid test will become a standard in general practitioners' offices for ischemic heart disease screening.
Market capitalization of the market segment - Medanalysis
Heart Test Laboratories has developed an AI-powered ECG device for early detection of heart disease. What is the scale of this innovation? The chart below shows the overall market capitalization of the medical analytics sector. Its growth reflects how artificial intelligence is helping make diagnostics more accurate and accessible.
Market capitalization of all companies included in a broad market index - GURU.Markets
The Heart Test Laboratories chart shows how the market is valuing a new approach to diagnosing heart disease. The company's market cap is based on its MyoVista device, which uses AI to analyze ECGs. This chart illustrates how technology is trying to make cardiology more accurate and predictive.
Book value capitalization of the company, segment and market as a whole
HSCS - Book value capitalization of the company Heart Test Laboratories
For Heart Test Laboratories, a developer of an AI-powered ECG device, book value represents its tangible assets: R&D equipment, inventory of components for the MyoVista device, and IT infrastructure. The chart shows how the company has invested in its technological and production capital.
HSCS - Share of the company's book capitalization Heart Test Laboratories within the market segment - Medanalysis
Heart Test Laboratories, Inc. creates cardiac diagnostic devices. Its tangible assets include production lines for its MyoVista ECG machine and R&D laboratories. The chart shows the company's control over this innovative medical manufacturing infrastructure in the field of cardiology.
Market segment balance sheet capitalization - Medanalysis
Heart Test Laboratories is a medical diagnostics company. Its model is knowledge-intensive in a capital-intensive industry. Its asset portfolio is enormous. Heart Test invests in R&D to develop its unique diagnostic test.
Book value of all companies included in the broad market index - GURU.Markets
Heart Test Labs' assets are not pacemakers, but rather MyoVista technology, which uses AI-powered ECG analysis for the early detection of heart disease. Its book value reflects its scientific and technological potential in non-invasive cardiac diagnostics.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - Heart Test Laboratories
Heart Test Laboratories is developing an AI-powered electrocardiograph for the early diagnosis of heart disease. Its value lies in its technology. The chart shows how the market perceives its potential for improving cardiac diagnostics.
Market to book capitalization ratio in a market segment - Medanalysis
Heart Test Laboratories is developing a medical device for the early diagnosis of heart disease using ECG and AI. The chart shows how the market is assessing its innovative technology and its potential to transform cardiac diagnostics.
Market to book capitalization ratio for the market as a whole
Heart Test Laboratories develops devices for diagnosing heart disease. Patents for AI-based ECG technology are its main asset. This chart shows the premium investors place on innovative medical technologies that can improve early diagnosis and save lives.
Debts of the company, segment and market as a whole
HSCS - Company debts Heart Test Laboratories
Heart Test Laboratories is developing an AI-powered medical device for the early diagnosis of heart disease. Bringing a new diagnostic device to market requires capital for clinical trials, approvals, and marketing. This chart shows how the company finances its journey from development to potential commercialization of its technology.
Market segment debts - Medanalysis
Heart Test Laboratories is developing a medical device for the early diagnosis of heart disease using artificial intelligence. Commercializing such a product requires significant investment. This chart shows how the company is funding its clinical trials and preparations for market launch.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio Heart Test Laboratories
Heart Test Laboratories is developing a device for diagnosing heart disease using ECGs. This chart shows its financial structure. For a medical technology company whose success depends on regulatory approval and medical acceptance, debt is a major risk until revenue is stable.
Market segment debt to market segment book capitalization - Medanalysis
Heart Test Laboratories is developing an AI-powered medical device for the early diagnosis of heart disease using ECGs. This chart shows the overall debt burden in the sector, helping to understand how the company finances its expensive clinical trials and the regulatory approval process for its innovative technology.
Debt to book value of all companies in the market
Heart Test Laboratories is developing a medical device for the early diagnosis of heart disease using AI. The company incurs significant costs during the product's launch. This chart shows the general financing terms, helping to understand the financing options—debt or equity—available to commercialize its technology.
P/E of the company, segment and market as a whole
P/E - Heart Test Laboratories
This metric for Heart Test Laboratories, a medical company developing heart tests, reflects expectations for its technology. The P/E (if established) will be based on investors' belief that its diagnostic method will be more accurate and convenient than existing ones and will be accepted by the medical community.
P/E of the market segment - Medanalysis
Heart Test Laboratories is a medical technology company that developed the MyoVista device for the early diagnosis of coronary heart disease using AI-powered ECG analysis. This chart shows the average rating for the sector, helping to understand how the market views this innovative diagnostic technology.
P/E of the market as a whole
Heart Test Laboratories is developing an AI-powered medical device for the early diagnosis of heart disease. Its valuation is a pure bet on the success of this technology. It is not tied to the general economic cycles reflected here, but depends entirely on the results of clinical trials and regulatory approval.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company Heart Test Laboratories
Heart Test Laboratories is developing MyoVista, a medical device using ECG for the early detection of heart disease. This graph reflects investor expectations regarding the commercialization of this technology. Future profitability depends on regulatory approvals and acceptance by the medical community.
%20P%2FE%20Heart%20Test%20Laboratories&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-Heart-Test-Laboratories&v=1772541333389 "Chart of the company's future (projected) P/E Heart Test Laboratories")
Future (projected) P/E of the market segment - Medanalysis
Heart Test Laboratories is developing an AI-powered medical device for the early detection of heart disease. Its valuation, relative to other companies in the medical diagnostics sector, reflects investors' opinions on its MyoVista technology. This is a bet that its non-invasive test will become an important tool for cardiologists.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Medanalysis&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Medanalysis&v=1772541333393 "Future (projected) P/E graph of the market segment - Medanalysis")
Future (projected) P/E of the market as a whole
Heart Test Laboratories is developing an AI-powered medical device for the early diagnosis of heart disease using ECG. The company's success depends on regulatory approval and physician acceptance of the technology. This chart reflects the overall risk appetite of investors. For companies bringing innovative diagnostic solutions to market, investor confidence in their commercial potential is crucial.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772541333400 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit Heart Test Laboratories
Heart Test Laboratories has developed a medical device, MyoVista, which uses ECG for the early detection of heart disease. Financial results shown here depend on the commercialization of this device and its acceptance by cardiologists as a new diagnostic tool.
Profit of companies in the market segment - Medanalysis
Heart Test Laboratories is developing an AI-powered medical device for the early diagnosis of heart disease. This chart shows the overall profitability of the medical diagnostics sector. It helps understand how prepared the market and physicians are for the adoption of new AI-based diagnostic tools that could change the standard of care.
Overall market profit
Heart Test Laboratories is developing a medical device for the early diagnosis of heart disease. This is an innovative product in the medical device market. Its success depends on FDA approval and acceptance by the medical community. The overall economic backdrop, reflected in this chart, is secondary to HSCS.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company Heart Test Laboratories
Heart Test Laboratories is developing an AI-powered medical device for the early diagnosis of heart disease. The company's future revenue depends on regulatory approval and adoption of its technology. This chart reflects analyst expectations for the commercialization of this innovative diagnostic tool.
%20profit%20of%20the%20company%20Heart%20Test%20Laboratories&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-Heart-Test-Laboratories&v=1772541333466 "Graph of future (projected) profit of the company Heart Test Laboratories")
Future (predicted) profit of companies in the market segment - Medanalysis
Heart Test Laboratories has developed MyoVista, a medical device that uses electrocardiography with AI-powered analysis for the early detection of heart disease. This chart shows forecasts for the medical testing sector. It illustrates how the use of artificial intelligence can improve diagnostic accuracy and accessibility, opening up new opportunities in a mature market.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Medanalysis&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Medanalysis&v=1772541333484 "Graph of future (predicted) profits of companies in a market segment - Medanalysis")
Future (predicted) profit of the market as a whole
This chart illustrates healthcare costs and the implementation of new diagnostic technologies. Heart Test Laboratories, a developer of cardiac tests, depends on the willingness of hospitals to purchase their equipment. Economic growth allows medical institutions to invest in innovation, while a recession forces them to cut costs.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772541333486 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - Heart Test Laboratories
Heart Test Laboratories is developing a medical device for the early diagnosis of heart disease. This figure reflects investors' assessment of its revenue potential. It's a bet that its technology will become a new standard in cardiology.
P/S market segment - Medanalysis
Heart Test Laboratories is developing a medical device using artificial intelligence for the early diagnosis of heart disease. This chart shows the average valuation in the medical analytics sector. It reflects the premium investors are willing to pay for innovative diagnostic tools that can save lives and reduce healthcare costs.
P/S of the market as a whole
Heart Test Laboratories, Inc. has developed the MyoVista device for the early diagnosis of heart disease using a next-generation ECG. Future revenue depends on the commercialization of this device. This chart helps estimate the premium investors are placing on this potentially breakthrough product in the vast field of cardiac diagnostics.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company Heart Test Laboratories
Heart Test Laboratories is developing an AI-powered medical device for the early diagnosis of heart disease using ECG. Future revenue depends on FDA approval and clinical implementation. The chart shows investors' confidence in its technology's potential to improve cardiac diagnostics.
%20P%2FS%20Heart%20Test%20Laboratories&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-Heart-Test-Laboratories&v=1772541333571 "The graph of the company's future (projected) P/S Heart Test Laboratories")
Future (projected) P/S of the market segment - Medanalysis
Heart Test Laboratories has developed a portable device, MyoVista, that uses AI-powered electrocardiography for the early detection of heart disease. This chart shows how the market assesses the commercial potential of this innovative diagnostic tool compared to other companies in the medical analytics sector.
%20P%2FS%20market%20segment%20graph%20-%20Medanalysis&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Medanalysis&v=1772541333589 "Future (projected) P/S market segment graph - Medanalysis")
Future (projected) P/S of the market as a whole
This shows the overall sentiment of investors in medical diagnostics. For Heart Test Laboratories, a developer of an AI-powered ECG device for early detection of heart disease, this is an indicator of innovation adoption. Market optimism supports the introduction of new technologies that can make diagnostics more accessible and accurate.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772541333611 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales Heart Test Laboratories
Heart Test Laboratories has developed the MyoVista medical device, which uses electrocardiography (ECG) for the early detection of heart disease. This chart will reflect revenue from sales of these devices to hospitals and clinics. Increased sales will indicate the acceptance of this new diagnostic technology by the medical community.
Sales of companies in the market segment - Medanalysis
Heart Test Laboratories is developing MyoVista, a medical device that uses electrocardiography for the early detection of heart disease. This graph illustrates the growth in the medical analytics sector. The company's technology could become a valuable screening tool, helping to identify heart problems early and save lives.
Overall market sales
Heart Test Laboratories is developing a medical device for the early diagnosis of heart disease using artificial intelligence. Demand for its technology will depend on its implementation in clinical practice. The overall economic environment, shown in this graph, influences healthcare budgets for the purchase of new diagnostic equipment.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company Heart Test Laboratories
Heart Test Laboratories is developing a medical device using artificial intelligence for the early diagnosis of heart disease using electrocardiogram (ECG) analysis. This chart shows analysts' expectations for the commercialization of this diagnostic technology and its adoption in medical practice.
%20sales%20of%20the%20company%20Heart%20Test%20Laboratories&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-Heart-Test-Laboratories&v=1772541333664 "Schedule of future (projected) sales of the company Heart Test Laboratories")
Future (projected) sales of companies in the market segment - Medanalysis
Heart Test Laboratories is developing an AI-powered medical device for the early diagnosis of heart disease. This graph illustrates expectations for the medical analytics sector. It reflects the enormous need for improved cardiac diagnostics, which represents a market opportunity for the company.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Medanalysis&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Medanalysis&v=1772541333693 "Schedule of future (projected) sales of companies in the market segment - Medanalysis")
Future (projected) sales of the market as a whole
Heart Test Laboratories, Inc., operating under the brand name HeartSciences, is developing a medical device for the early diagnosis of heart disease using artificial intelligence. The company's success depends on regulatory approval. This chart, reflecting general trends in healthcare, shows the growing demand for preventative diagnostics and AI-based technologies.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772541333716 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality Heart Test Laboratories
Heart Test Laboratories has developed an AI-powered device for the early diagnosis of heart disease using ECG. This chart shows the financial status at the commercialization stage. Profitability will depend on sales of the device to doctors and clinics and on proof of its clinical and cost effectiveness.
Market segment marginality - Medanalysis
Heart Test Laboratories is developing the MyoVista medical device for the early diagnosis of heart disease using ECG. Profitability in the medical device sector depends on the accuracy of the device and its acceptance by physicians. This graph shows the average profitability in the industry, allowing one to assess the commercial potential of Heart Test Laboratories' technology.
Market marginality as a whole
Heart Test Laboratories is developing an AI-powered medical device for the early diagnosis of heart disease. This total market revenue graph does not impact the company. Its success depends on regulatory approvals and physician acceptance of its technology. The market is driven by a significant need for improved cardiac diagnostics.
Employees in the company, segment and market as a whole
Number of employees in the company Heart Test Laboratories
Heart Test Laboratories is developing an AI-powered medical device for the early diagnosis of heart disease. This graphic shows the small team of engineers and clinicians working to bring this innovative diagnostic tool to market.
Share of the company's employees Heart Test Laboratories within the market segment - Medanalysis
Heart Test Laboratories has developed an innovative AI-powered electrocardiograph for the early diagnosis of heart disease. This chart shows the percentage of biomedical engineers and machine learning specialists the company employs in cardiac diagnostics, reflecting its talent pool for creating breakthrough medical technology.
Number of employees in the market segment - Medanalysis
Heart Test Laboratories is developing an AI-powered medical device for the early diagnosis of heart disease using ECGs. This graph illustrates how artificial intelligence is becoming a powerful tool in medicine, creating a demand for machine learning specialists, cardiologists, and engineers to develop smart diagnostic systems.
Number of employees in the market as a whole
Heart Test Laboratories is developing new methods for diagnosing heart disease. Advances in this field could save millions of lives and reduce healthcare costs. This graph reflects the scale of the healthcare sector, and innovations from companies like HSCS are key to its long-term effectiveness and sustainability.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company Heart Test Laboratories (HSCS)
Heart Test Laboratories is developing a medical device (MyoVista) for the early diagnosis of heart disease. This chart represents the net intellectual capital value of the company. Its main asset is its patented ECG technology. The chart shows how highly the market values this innovative diagnostic technology and its market potential per engineer.
%20of%20the%20company%20Heart%20Test%20Laboratories%20(HSCS)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-Heart-Test-Laboratories-HSCS&v=1772541333795 "Chart of market capitalization per employee (in thousands of dollars) of the company Heart Test Laboratories (HSCS)")
Market capitalization per employee (in thousands of dollars) in the market segment - Medanalysis
Heart Test Laboratories is developing a medical device for the early diagnosis of heart disease using ECG. In the medical device sector, value is determined by the uniqueness and precision of the technology. The chart shows how much investors are betting on their product and the team capable of commercializing it.
%20by%20market%20segment%20-%20Medanalysis&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Medanalysis&v=1772541333802 "Market capitalization per employee (in thousands of dollars) by market segment - Medanalysis")
Market capitalization per employee (in thousands of dollars) for the overall market
Heart Test Laboratories, Inc. has developed a device for the early diagnosis of heart disease using AI. This chart shows the average value the market assigns to one employee, demonstrating the high valuation of technologies at the intersection of medicine and AI.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772541333827 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company Heart Test Laboratories (HSCS)
Heart Test Laboratories is a medical company developing a device for the early detection of heart problems (an ECG with AI). It's an R&D company. This graph likely shows the company's per-employee loss. It reflects how much the company invests in each engineer to create its product.
%20Chart%20Heart%20Test%20Laboratories%20(HSCS)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-Heart-Test-Laboratories-HSCS&v=1772541333856 "Company Profit Per Employee (in thousands of dollars) Chart Heart Test Laboratories (HSCS)")
Profit per employee (in thousands of dollars) in the market segment - Medanalysis
Heart Test Laboratories is developing a medical device using artificial intelligence for the early diagnosis of heart disease. It's a company at the intersection of medicine and IT. At the commercialization stage, this chart shows how successfully the sales team is bringing an innovative product to market, reflecting the financial return on each employee and the adoption of the technology by the medical community.
%20in%20the%20market%20segment%20-%20Medanalysis&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Medanalysis&v=1772541333862 "Chart of profit per employee (in thousands of dollars) in the market segment - Medanalysis")
Profit per employee (in thousands of dollars) for the market as a whole
Heart Test Laboratories (HSCS) is a MedTech company developing MyoVista, a noninvasive 12-lead ECG device that (they claim) uses AI for the early diagnosis of heart disease. It is an R&D AI/MedTech company. This chart shows the market average profitability per employee. For HSCS (which is currently investing in R&D), this is a benchmark.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772541333863 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee Heart Test Laboratories (HSCS)
Heart Test Laboratories is developing a medical device for the early diagnosis of heart disease. This graph shows the path from development to market. Growth in this indicator will indicate the successful implementation of the technology in clinical practice and the company's ability to generate revenue for its team.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-Heart-Test-Laboratories-HSCS&v=1772541333872 "Sales chart per company employee Heart Test Laboratories (HSCS)")
Sales per employee in the market segment - Medanalysis
Heart Test Laboratories (HSCS) develops a medical device (MyoVista) for the early diagnosis of heart disease using ECG. It's a medtech company. This chart shows the average revenue per employee in the segment. It helps evaluate how effectively the HSCS team is commercializing its diagnostic technology compared to competitors.
Sales per employee for the market as a whole
Heart Test Laboratories (HSCS) is developing a medical device (MyoVista) that uses AI for the early diagnosis of heart disease. The company is in the early stages of commercialization. This chart shows how effectively their team (R&D, sales) is beginning to generate revenue from sales of their innovative diagnostic device.
Short shares by company, segment and market as a whole
Shares shorted by company Heart Test Laboratories (HSCS)
Heart Test Laboratories (HSCS) is developing an ECG-based device (MyoVista) for the early diagnosis of heart disease. This chart shows the bets that their technology is not unique. The "bears" believe their "improved ECG" offers no real advantages over standard methods and will not be used by doctors.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-Heart-Test-Laboratories-HSCS&v=1772541333969 "Short Shares Chart for the Company Heart Test Laboratories (HSCS)")
Shares shorted by market segment - Medanalysis
Heart Test Laboratories (HSCS) is developing a medical device (MyoVista)—a 12-electrode ECG machine that they claim can detect heart disease at an early stage. This chart shows the overall short position in the medical diagnostics sector. Its rise signals investor doubts about the ability of companies in the sector to prove the superiority of new diagnostic devices.
Shares shorted by the overall market
Heart Test Labs (HSCS) is an R&D company developing cardiac diagnostics. It's a speculative bet. When this market fear indicator rises, investors' risk appetite plummets. They sell off unprofitable stocks like HSCS, whose fate depends on R&D and regulatory approval.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator Heart Test Laboratories (HSCS)
Heart Test Laboratories (HSCS) is developing the MyoVista device for early diagnosis of heart disease using ECG and AI. This is a promising segment of medical technology. This oscillator measures price momentum. It helps determine when investor expectations (above 70) for FDA approval or "overselling" (below 30) amid delays are peaking.
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-Heart-Test-Laboratories-HSCS&v=1772541334015 "RSI 14 indicator chart for the company's stock Heart Test Laboratories (HSCS)")
RSI 14 Market Segment - Medanalysis
Heart Test Laboratories is a MedTech company developing the non-invasive MyoVista device for the early diagnosis of heart disease using AI. This chart shows the overall sentiment in the medical diagnostics and testing sector. It helps understand how investors view the industry and how HSCS compares to competitors using its new technology.
RSI 14 for the overall market
Heart Test Labs (HSCS), a medical equipment developer, sees both hospital budgets and risk appetite in this chart. In a euphoric mood, investors are ready to finance the "future of medicine," and hospitals are ready to buy expensive innovations. In a panic, investors flee unprofitable R&D projects, and hospitals freeze capital expenditures.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast HSCS (Heart Test Laboratories)
Heart Test Laboratories is developing MyoVista, an AI-powered ECG analysis device for the early detection of heart disease. This chart shows the analysts' average forecast. Their targets are based on successful FDA approval, clinical data supporting accuracy, and commercialization plans.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-HSCS-Heart-Test-Laboratories&v=1772541334040 "A chart showing analyst consensus forecasts for the expected stock price. HSCS (Heart Test Laboratories)")
The difference between the consensus estimate and the actual stock price HSCS (Heart Test Laboratories)
Heart Test Laboratories is a medical technology company developing MyoVista, an ECG device that uses AI for the early detection of heart disease. This chart shows the difference between the market estimate and the consensus forecast. It reveals whether experts believe their "smart" ECG can become the new standard in diagnostics.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-HSCS-Heart-Test-Laboratories&v=1772541334047 "A chart showing the difference between the consensus forecast and the actual stock price. HSCS (Heart Test Laboratories)")
Analyst consensus forecast for stock prices by market segment - Medanalysis
Heart Test Laboratories (HSCS) is a medical company developing MyoVista, a non-invasive ECG device that uses AI for the early detection of heart disease. This chart shows general expectations for the medical testing sector. It reflects whether experts believe in "AI diagnostics" in cardiology.
Analysts' consensus forecast for the overall market share price
Heart Test Laboratories (HSCS) is a medical technology company that aims to "predict" heart attacks. They are developing MyoVista, an ECG device that uses AI to detect heart disease at an early stage. This chart shows the overall risk appetite, reflecting the market's willingness to fund R&D companies seeking to improve basic diagnostics.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index Heart Test Laboratories
Heart Test Labs (HSCS) is ECG 2.0. Their signature product is MyoVista, an ECG machine that uses AI to predict (not just measure) heart conditions (such as diastolic dysfunction) at an early stage. This chart summarizes their implementation history. It reflects their (slow) path to FDA approval and their struggle to digitize cardiology.
AKIMA Market Segment Index - Medanalysis
Heart Test Laboratories (HSCS) is striving to improve the ECG. The company has developed MyoVista, a diagnostic device that uses AI and 12 leads to early detection of heart conditions invisible on a standard ECG. This graph shows the average index for the segment, helping to assess how this smart diagnostic compares to the average.
The AKIM Index for the overall market
Heart Test Laboratories is a medtech company using AI to improve ECGs and early detection of heart disease (MyoVista). This chart, which reflects the market average, is a backdrop. It helps assess how HSCS, a diagnostic innovator, stacks up against overall macroeconomic trends.
